NasdaqCM:AEZS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Aeterna Zentaris's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AEZS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.1%

AEZS

-3.9%

US Biotechs

1.3%

US Market


1 Year Return

-77.6%

AEZS

27.2%

US Biotechs

14.9%

US Market

Return vs Industry: AEZS underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: AEZS underperformed the US Market which returned 12.5% over the past year.


Shareholder returns

AEZSIndustryMarket
7 Day-3.1%-3.9%1.3%
30 Day24.1%-3.5%4.7%
90 Day-38.9%7.4%17.1%
1 Year-77.6%-77.6%28.5%27.2%17.3%14.9%
3 Year-75.3%-75.3%26.2%22.0%38.9%29.9%
5 Year-97.1%-97.1%-4.2%-9.7%71.3%52.8%

Price Volatility Vs. Market

How volatile is Aeterna Zentaris's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aeterna Zentaris undervalued compared to its fair value and its price relative to the market?

6.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AEZS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AEZS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AEZS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AEZS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AEZS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AEZS is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Aeterna Zentaris forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aeterna Zentaris has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aeterna Zentaris performed over the past 5 years?

41.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AEZS is currently unprofitable.

Growing Profit Margin: AEZS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AEZS is unprofitable, but has reduced losses over the past 5 years at a rate of 41.1% per year.

Accelerating Growth: Unable to compare AEZS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AEZS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.5%).


Return on Equity

High ROE: AEZS has a negative Return on Equity (-20.87%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aeterna Zentaris's financial position?


Financial Position Analysis

Short Term Liabilities: AEZS's short term assets ($11.0M) exceed its short term liabilities ($3.2M).

Long Term Liabilities: AEZS's short term assets ($11.0M) do not cover its long term liabilities ($14.8M).


Debt to Equity History and Analysis

Debt Level: AEZS is debt free.

Reducing Debt: AEZS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AEZS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AEZS has less than a year of cash runway if free cash flow continues to grow at historical rates of 23% each year.


Next Steps

Dividend

What is Aeterna Zentaris's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AEZS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AEZS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AEZS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AEZS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AEZS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Klaus Paulini

0.83

Tenure

US$289,676

Compensation

Dr. Klaus Paulin, PhD, has been President, Chief Executive Officer and Director of Aeterna Zentaris Inc., since October 4, 2019. Dr. Paulini had been as Managing Director of German subsidiary at Aeterna Ze ...


CEO Compensation Analysis

Compensation vs Market: Klaus's total compensation ($USD289.68K) is below average for companies of similar size in the US market ($USD608.75K).

Compensation vs Earnings: Klaus's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Klaus Paulini
President0.83yrUS$289.68kno data
Leslie Auld
Senior VP & CFO1.92yrsUS$194.06kno data
Nicola Ammer
Chief Medical Officer & VP of Clinical Development2.58yrsUS$177.36kno data
Matthias Gerlach
Vice President of Manufacturing & Supply Chainno dataUS$205.45kno data
Olaf Althaus
2.17yrsno datano data
Eckhard Guenther
VP of Business Development & Alliance Management and Managing Director AEZS Germany0.58yrno datano data
Amélie Métivier
Assistant Secretary11.33yrsno datano data

2.0yrs

Average Tenure

Experienced Management: AEZS's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Klaus Paulini
President0.83yrUS$289.68kno data
Gilles Gagnon
Independent Director0.58yrUS$980.55kno data
Gerald Batist
Member of the Scientific Advisory Boardno datano datano data
Hartmut Michel
Member of the Scientific Advisory Boardno datano datano data
Marcel Verheij
Member of the Scientific Advisory Boardno datano datano data
René Frydman
Member of the Scientific Advisory Boardno datano datano data
Alan DeCherney
Member of the Scientific Advisory Boardno datano datano data
Klaus Diedrich
Member of the Scientific Advisory Boardno datano datano data
Frans Debruyne
Member of the Scientific Advisory Boardno datano datano data
Ulf Rapp
Member of the Scientific Advisory Boardno datano datano data
Carolyn Egbert
Independent Chairman4.25yrsUS$177.01k0.0047%
$ 874.8
Pierre-Yves Desbiens
Independent Director0.33yrno datano data

0.7yrs

Average Tenure

Experienced Board: AEZS's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AEZS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.4%.


Top Shareholders

Company Information

Aeterna Zentaris Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aeterna Zentaris Inc.
  • Ticker: AEZS
  • Exchange: NasdaqCM
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$25.088m
  • Listing Market Cap: CA$18.732m
  • Shares outstanding: 41.13m
  • Website: https://www.zentaris.com

Number of Employees


Location

  • Aeterna Zentaris Inc.
  • 315 Sigma Drive
  • Suite 302D
  • Summerville
  • South Carolina
  • 29486
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AEZSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDDec 1995
AEZSTSX (The Toronto Stock Exchange)YesCommon SharesCACADDec 1995
ET82DB (Deutsche Boerse AG)YesCommon SharesDEEURDec 1995
0UGBLSE (London Stock Exchange)YesCommon SharesGBCADDec 1995

Biography

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 00:22
End of Day Share Price2020/07/31 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.